NASDAQ:ELVN Enliven Therapeutics (ELVN) Stock Price, News & Analysis $27.31 +2.29 (+9.15%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$25.19▼$27.4850-Day Range$20.20▼$27.3152-Week Range$9.80▼$27.52Volume202,877 shsAverage Volume350,262 shsMarket Capitalization$1.28 billionP/E RatioN/ADividend YieldN/APrice Target$33.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Enliven Therapeutics alerts: Email Address Enliven Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.33 Rating ScoreUpside/Downside20.8% Upside$33.00 Price TargetShort InterestBearish19.44% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.46Based on 4 Articles This WeekInsider TradingSelling Shares$25.39 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($2.26) to ($2.74) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.66 out of 5 starsMedical Sector430th out of 936 stocksPharmaceutical Preparations Industry197th out of 436 stocks 2.7 Analyst's Opinion Consensus RatingEnliven Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.33, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageEnliven Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Enliven Therapeutics' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted19.44% of the float of Enliven Therapeutics has been sold short.Short Interest Ratio / Days to CoverEnliven Therapeutics has a short interest ratio ("days to cover") of 16.3, which indicates bearish sentiment.Change versus previous monthShort interest in Enliven Therapeutics has recently decreased by 10.41%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldEnliven Therapeutics does not currently pay a dividend.Dividend GrowthEnliven Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ELVN. Previous Next 2.5 News and Social Media Coverage News SentimentEnliven Therapeutics has a news sentiment score of 0.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Enliven Therapeutics this week, compared to 2 articles on an average week.MarketBeat Follows1 people have added Enliven Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Enliven Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $25,390,954.00 in company stock.Percentage Held by Insiders29.20% of the stock of Enliven Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions95.08% of the stock of Enliven Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Enliven Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Enliven Therapeutics are expected to decrease in the coming year, from ($2.26) to ($2.74) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Enliven Therapeutics is -14.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Enliven Therapeutics is -14.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEnliven Therapeutics has a P/B Ratio of 4.57. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Enliven Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss RatingsNvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.Find out details on these three critical Nvidia partners immediately. About Enliven Therapeutics Stock (NASDAQ:ELVN)Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.Read More ELVN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ELVN Stock News HeadlinesJuly 18, 2024 | insidertrades.comInsider Selling: Enliven Therapeutics, Inc. (NASDAQ:ELVN) Director Sells 1,270 Shares of StockJuly 17, 2024 | insidertrades.comEnliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl Sells 3,000 SharesJuly 27, 2024 | DTI (Ad)How to build the ultimate dividend portfolioThere’s a free dividend workshop that shows how anyone can build the ultimate dividend workshop in 3 basic steps? PLUS: You’ll get the names and tickers of the Best Dividend Stocks for FREE… This way, by the time you finish the workshop you’ll be fully equipped with the knowledge to start unlocking dividend checks for yourself… Over and over again.July 2, 2024 | insidertrades.comInsider Selling: Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Sells 4,250 Shares of StockJune 28, 2024 | insidertrades.comEnliven Therapeutics, Inc. (NASDAQ:ELVN) CEO Samuel Kintz Sells 12,000 SharesJuly 19, 2024 | americanbankingnews.comRichard A. Heyman Sells 1,270 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) StockJuly 19, 2024 | americanbankingnews.comShort Interest in Enliven Therapeutics, Inc. (NASDAQ:ELVN) Rises By 5.6%July 18, 2024 | americanbankingnews.comBenjamin Hohl Sells 3,000 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) StockJuly 27, 2024 | DTI (Ad)How to build the ultimate dividend portfolioThere’s a free dividend workshop that shows how anyone can build the ultimate dividend workshop in 3 basic steps? PLUS: You’ll get the names and tickers of the Best Dividend Stocks for FREE… This way, by the time you finish the workshop you’ll be fully equipped with the knowledge to start unlocking dividend checks for yourself… Over and over again.July 18, 2024 | americanbankingnews.comAnish Patel Sells 17,475 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) StockJuly 17, 2024 | americanbankingnews.comEnliven Therapeutics, Inc. (NASDAQ:ELVN) COO Anish Patel Sells 30,978 Shares of StockMay 29, 2024 | globenewswire.comEnliven Therapeutics to Present at Two Upcoming Investor ConferencesMay 29, 2024 | markets.businessinsider.comStrong Buy Rating for Enliven Therapeutics’ ELVN-001 Amid Favorable Market DynamicsMay 15, 2024 | finanznachrichten.deEnliven Therapeutics, Inc.: Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business UpdateMay 15, 2024 | investorplace.comELVN Stock Earnings: Enliven Therapeutics Beats EPS for Q1 2024May 14, 2024 | globenewswire.comEnliven Therapeutics Reports First Quarter Financial Results and Provides a Business UpdateApril 28, 2024 | nasdaq.comCommit To Purchase Enliven Therapeutics At $10, Earn 11.2% Annualized Using OptionsApril 26, 2024 | markets.businessinsider.comBuy Rating Affirmed for Apellis Pharmaceuticals Amid Positive Outlook and Growth PotentialSee More Headlines Receive ELVN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Enliven Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/14/2024Today7/27/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ELVN CUSIPN/A CIK1672619 Webimaratx.com Phone617-927-9989FaxN/AEmployees46Year FoundedN/APrice Target and Rating Average Stock Price Target$33.00 High Stock Price Target$34.00 Low Stock Price Target$32.00 Potential Upside/Downside+20.8%Consensus RatingBuy Rating Score (0-4)3.33 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.93) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-71,580,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-28.83% Return on Assets-27.05% Debt Debt-to-Equity RatioN/A Current Ratio13.47 Quick Ratio13.47 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.97 per share Price / Book4.57Miscellaneous Outstanding Shares47,040,000Free Float33,302,000Market Cap$1.28 billion OptionableOptionable Beta1.11 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesMr. Samuel S. Kintz M.B.A. (Age 38)Co-Founder, CEO, Secretary & Director Comp: $597kDr. Helen Louise Collins M.D. (Age 61)Chief Medical Officer Comp: $558kDr. Joseph P. Lyssikatos Ph.D. (Age 59)Co-Founder, Chief Scientific Officer & Directors Dr. Galya D. Blachman Esq. (Age 47)Ph.D., Chief Legal Officer & Head of Business Development Key CompetitorsAvadel PharmaceuticalsNASDAQ:AVDLFulcrum TherapeuticsNASDAQ:FULCEditas MedicineNASDAQ:EDITDelcath SystemsNASDAQ:DCTHbluebird bioNASDAQ:BLUEView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 37,632 shares on 7/26/2024Ownership: 0.243%Anish PatelSold 30,978 sharesTotal: $775,998.90 ($25.05/share)Richard A HeymanSold 1,270 sharesTotal: $31,496.00 ($24.80/share)Anish PatelSold 17,475 sharesTotal: $438,098.25 ($25.07/share)Benjamin HohlSold 3,000 sharesTotal: $75,210.00 ($25.07/share)View All Insider TransactionsView All Institutional Transactions ELVN Stock Analysis - Frequently Asked Questions How have ELVN shares performed this year? Enliven Therapeutics' stock was trading at $13.84 at the start of the year. Since then, ELVN shares have increased by 97.3% and is now trading at $27.31. View the best growth stocks for 2024 here. How were Enliven Therapeutics' earnings last quarter? Enliven Therapeutics, Inc. (NASDAQ:ELVN) posted its quarterly earnings results on Tuesday, May, 14th. The company reported ($0.54) EPS for the quarter, topping the consensus estimate of ($0.58) by $0.04. Who are Enliven Therapeutics' major shareholders? Top institutional shareholders of Enliven Therapeutics include Bank of New York Mellon Corp (0.24%). Insiders that own company stock include Samuel Kintz, 5Am Partners Vi, Llc, Anish Patel, Rishi Gupta, Rahul D Ballal, Benjamin Hohl and Joseph P Lyssikatos. View institutional ownership trends. How do I buy shares of Enliven Therapeutics? Shares of ELVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ELVN) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredJ.P. Morgan’s DIRE WarningWhen the largest bank in the U.S. says a crisis is coming - you NEED to listen. The Wall Street Journal war...Behind the Markets | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enliven Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enliven Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
